Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, E (Q34407296)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, E |
scientific article |
Statements
1 reference
Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, E (English)
1 reference
Serruys PW
1 reference
Karsch KR
1 reference
Preisack MB
1 reference
Baildon R
1 reference
Eschenfelder V
1 reference
Foley D
1 reference
Garcia EJ
1 reference
Kaltenbach M
1 reference
Meisner C
1 reference
Selbmann HK
1 reference
Shiu MF
1 reference
Sujatta M
1 reference
Bonan R
1 reference
1 November 1996
1 reference
1 reference
28
1 reference
1437-1443
1 reference
Identifiers
1 reference
1 reference